BioCentury

Current Editions

March 25, 2024
Treating obesity by quelling inflammation in the brain

How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone

Product Development

Anti-China bills portend massive blow to biotech: BioCentury survey

Overwhelming majority of biotechs expect pipeline setbacks; many oppose BIO’s reversal 

Politics, Policy & Law

Biotech is benefiting from belt-tightening, but some pain still to come — Bruce Booth 

Atlas Venture partner’s views on the capital markets, modality plays and industry efficiency, on The BioCentury Show

Finance

Product Development

Non-profit biotech aims to revive stalled ultrarare therapies

Orphan Therapeutics Accelerator will pursue hybrid non-profit, commercial model 

Emerging Company Profile

Reverb: redirecting endogenous cytokines to tumors

Vancouver-based Reverb is making bispecific antibodies to nab cytokines and deliver them to a desired cell or tissue

Data Byte

Radiopharmaceuticals could soon get their first blockbuster

Pluvicto’s steep launch appears on track to surpass $1B in sales this year

EMA’s CHMP backs approval of Novartis’ complement drug

March decisions also include label extensions for UCB’s Bimzelx and Astellas’ Xtandi. Takeda pulls an application for Adcetris

WuXi AppTec report shows CDMO’s integration in U.S. biopharma sector

More than 60% of company’s revenues derived from the U.S.

Discovery & Translation

Regulation

Lenmeldy: an example of what it takes to get an ultrarare disease drug across the FDA finish line

A small dataset lacking a randomized control group can be enough when the efficacy signal is big and the unmet need severe

Politics, Policy & Law

Gallagher’s resignation may slow Biosecure Act

A pause would give lobbyists time to reduce harms to biopharma companies

Congress broadening anti-China life sciences focus

Senators investigating biotech, calling for export restrictions

Deals

AZ deepens radiopharma commitment via $2B Fusion takeout

Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto

Finance

Venture report: Mirador’s $400M launch; megarounds for Clasp, Capstan, Engrail

Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience

Public equity report: Galderma rises after $2B IPO; Contineum, Boundless prep U.S. listings

Plus Madrigal’s follow-on is among the year’s largest, and PureTech returns cash to shareholders following Karuna takeout

Biopharma Stock Performers

Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.

BioCentury ISSN 1097-7201